Fragmented Lactic Acid Bacterial Cells Activate Peroxisome Proliferator-Activated Receptors and Ameliorate Dyslipidemia in Obese Mice

Journal of Agricultural and Food Chemistry

Volumn 64, Issue 12, 2016, Pages 2549-2559

  Nakamura, Futoshi ^a   Ishida, Yu ^a   Sawada, Daisuke ^a   Ashida, Nobuhisa ^a   Sugawara, Tomonori ^a   Sakai, Manami ^b   Goto, Tsuyoshi ^b   Kawada, Teruo ^b   Fujiwara, Shigeru ^a  

^a Asahi Soft Drinks Co Ltd   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

cell fragmentation; dyslipidemia; lactic acid bacteria; peroxisome proliferator activated receptors

Indexed keywords

BACTERIA; CHEMICAL ACTIVATION; CHOLESTEROL; CYTOLOGY; LIPOPROTEINS; MAMMALS; ORGANIC SOLVENTS; POLYPEPTIDES; SOLVENT EXTRACTION;

ACTIVATION ABILITY; DYSLIPIDEMIAS; FOOD MANUFACTURING; HIGH-DENSITY LIPOPROTEINS; LACTIC ACID BACTERIA; LOW DENSITY LIPOPROTEINS; METABOLIC DISORDERS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR;

LACTIC ACID;

HIGH DENSITY LIPOPROTEIN; LACTIC ACID; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

AGONISTS; ANIMAL; ATHEROSCLEROSIS; BLOOD; DYSLIPIDEMIA; INSULIN RESISTANCE; METABOLISM; MOUSE; MOUSE MUTANT; OBESITY; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; DYSLIPIDEMIAS; INSULIN RESISTANCE; LACTIC ACID; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MICE; MICE, OBESE; OBESITY; PPAR ALPHA; PPAR GAMMA; TRIGLYCERIDES;

EID: 84963818154     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/acs.jafc.5b05827     Document Type: Article

References (33)

1. Kaur, J. A comprehensive review on metabolic syndrome Cardiol. Res. Pract. 2014, 2014, 943162 10.1155/2014/943162
2. Mulè, G.; Calcaterra, I.; Nardi, E.; Cerasola, G.; Cottone, S. Metabolic syndrome in hypertensive patients: an unholy alliance World J. Cardiol. 2014, 6 (9) 890-907 10.4330/wjc.v6.i9.890
3. Grundy, S. M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome Circulation 1997, 95 (1) 1-4 10.1161/01.CIR.95.1.1
4. Bosomworth, N. J. Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes Can. Fam. Physician 2013, 59, 1169-1180
5. Mann, G. V. A factor in yogurt which lowers cholesteremia in man Atherosclerosis 1977, 26 (3) 335-340 10.1016/0021-9150(77)90086-7
6. Agerbaek, M.; Gerdes, L. U.; Richelsen, B. Hypocholesterolaemic effect of a new fermented milk product in healthy middle-aged men Eur. J. Clin. Nutr. 1995, 49, 346-352
7. Bertolami, M. C.; Faludi, A. A.; Batlouni, M. Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia Eur. J. Clin. Nutr. 1999, 53 (2) 97-101 10.1038/sj.ejcn.1600683
8. Kawase, M.; Hashimoto, H.; Hosoda, M.; Morita, H.; Hosono, A. Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure J. Dairy Sci. 2000, 83 (2) 255-263 10.3168/jds.S0022-0302(00)74872-7
9. Wang, C.; Wu, S.; Fang, J.; Wang, Y.; Shyu, Y. Cardiovascular and intestinal protection of cereal pastes fermented with lactic acid bacteria in hyperlipidemic hamsters Food Res. Int. 2012, 48 (2) 428-434 10.1016/j.foodres.2012.05.006
10. Ogawa, A.; Kadooka, Y.; Kato, K.; Shirouchi, B.; Sato, M. Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects Lipids Health Dis. 2014, 13 (1) 36 10.1186/1476-511X-13-36
11. Thompson, L. U.; Jenkins, D. J.; Amer, M. A.; Reichert, R.; Jenkins, A.; Kamulsky, J. The effect of fermented and unfermented milks on serum cholesterol Am. J. Clin. Nutr. 1982, 36, 1106-1111
12. Massey, L. K. Effect of changing milk and yogurt consumption on human nutrient intake and serum lipoproteins J. Dairy Sci. 1984, 67 (2) 255-262 10.3168/jds.S0022-0302(84)81297-7
13. McNamara, D.; Lowell, A.; Sabb, J. Effect of yogurt intake on plasma lipid and lipoprotein levels in normolipidemic males Atherosclerosis 1989, 79 (2-3) 167-171 10.1016/0021-9150(89)90121-4
14. Richelsen, B.; Kristensen, K.; Pedersen, S. B. Long-term (6 months) effect of a new fermented milk product on the level of plasma lipoproteins-a placebo-controlled and double blind study Eur. J. Clin. Nutr. 1996, 50, 811-815
15. de Roos, N. M.; Schouten, G.; Katan, M. B. Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels Eur. J. Clin. Nutr. 1999, 53 (4) 277-280 10.1038/sj.ejcn.1600722
16. Chen, Z.; Ma, K. Y.; Liang, Y.; Peng, C.; Zuo, Y. Role and classification of cholesterol-lowering functional foods J. Funct. Foods 2011, 3 (2) 61-69 10.1016/j.jff.2011.02.003
17. Grygiel-Górniak, B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review Nutr. J. 2014, 13 (1) 17 10.1186/1475-2891-13-17
18. Lefebvre, P.; Chinetti, G.; Fruchart, J. C.; Staels, B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis J. Clin. Invest. 2006, 116 (3) 571-580 10.1172/JCI27989
19. Semple, R. K.; Chatterjee, V. K.; O'Rahilly, S. PPAR gamma and human metabolic disease J. Clin. Invest. 2006, 116 (3) 581-589 10.1172/JCI28003
20. Munigoti, S.; Harinarayan, C. Role of Glitazars in atherogenic dyslipidemia and diabetes: two birds with one stone? Indian J. Endocrinol. Metab. 2014, 18 (3) 283-287 10.4103/2230-8210.131134
21. Usuda, D.; Kanda, T. Peroxisome proliferator-activated receptors for hypertension World J. Cardiol. 2014, 6 (8) 744-754 10.4330/wjc.v6.i8.744
22. Agrawal, R. The first approved agent in the Glitazar's class: saroglitazar Curr. Drug Targets 2014, 15 (2) 151-155 10.2174/13894501113149990199
23. Kim, Y. I.; Hirai, S.; Goto, T.; Ohyane, C.; Takahashi, H.; Tsugane, T.; Konishi, C.; Fujii, T.; Inai, S.; Iijima, Y.; Aoki, K.; Shibata, D.; Takahashi, N.; Kawada, T. Potent PPARalpha activator derived from tomato juice, 13-oxo-9,11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice PLoS One 2012, 7, e31317 10.1371/journal.pone.0031317
24. Adams, C. A. The probiotic paradox: live and dead cells are biological response modifiers Nutr. Res. Rev. 2010, 23 (01) 37-46 10.1017/S0954422410000090
25. Taverniti, V.; Guglielmetti, S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept) Genes Nutr. 2011, 6 (3) 261-274 10.1007/s12263-011-0218-x
26. Takahashi, N.; Kawada, T.; Goto, T.; Yamamoto, T.; Taimatsu, A.; Matsui, N.; Kimura, K.; Saito, M.; Hosokawa, M.; Miyashita, K.; Fushiki, T. Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes FEBS Lett. 2002, 514 (2-3) 315-322 10.1016/S0014-5793(02)02390-6
27. Takahashi, N.; Kawada, T.; Goto, T.; Kim, C.; Taimatsu, A.; Egawa, K.; Yamamoto, T.; Jisaka, M.; Nishimura, K.; Yokota, K.; Yu, R.; Fushiki, T. Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism FEBS Lett. 2003, 550 (1-3) 190-194 10.1016/S0014-5793(03)00859-7
28. Miura, Y.; Hosono, M.; Oyamada, C.; Odai, H.; Oikawa, S.; Kondo, K. Dietary isohumulones, the bitter components of beer, raise plasma HDL-cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARalpha activations in C57BL/6 mice Br. J. Nutr. 2005, 93 (04) 559-567 10.1079/BJN20041384
29. Shimura, M.; Hasumi, A.; Minato, T.; Hosono, M.; Miura, Y.; Mizutani, S.; Kondo, K.; Oikawa, S.; Yoshida, A. Isohumulones modulate blood lipid status through the activation of PPAR alpha Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2005, 1736, 51-60 10.1016/j.bbalip.2005.06.008
30. Friedewald, W. T.; Levy, R. I.; Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin. Chem. 1972, 18, 499-502
31. Hiuge, A.; Tenenbaum, A.; Maeda, N.; Benderly, M.; Kumada, M.; Fisman, E. Z.; Tanne, D.; Matas, Z.; Hibuse, T.; Fujita, K.; Nishizawa, H.; Adler, Y.; Motro, M.; Kihara, S.; Shimomura, I.; Behar, S.; Funahashi, T. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level Arterioscler., Thromb., Vasc. Biol. 2007, 27, 635-641 10.1161/01.ATV.0000256469.06782.d5
32. Uchida, A.; Slipchenko, M. N.; Cheng, J.; Buhman, K. K. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, alters triglyceride metabolism in enterocytes of mice Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2011, 1811 (3) 170-176 10.1016/j.bbalip.2010.12.011
33. Kimura, R.; Takahashi, N.; Murota, K.; Yamada, Y.; Niiya, S.; Kanzaki, N.; Murakami, Y.; Moriyama, T.; Goto, T.; Kawada, T. Activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes Biochem. Biophys. Res. Commun. 2011, 410 (1) 1-6 10.1016/j.bbrc.2011.05.057